Brain Cancer News and Research

RSS

There are two main types of brain cancer. Primary brain cancer starts in the brain. Metastatic brain cancer starts somewhere else in the body and moves to the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Also called glioma, meningioma.

Kids are at risk of biological damage results from microwave radiation emitted by wireless devices

A scholarly article on wireless safety, published online in the Journal of Microscopy and Ultrastructure, reports that children and fetuses are the most at risk from neurological and biological damage that results from microwave radiation emitted by wireless devices, due to the higher rate of absorption of microwave radiation by children than by adults.

6 Aug 2014

CCC study provides hope that SapC-DOPS could be used for metastatic brain cancer treatment

Over half of patients being seen in the clinic for a diagnosed brain tumor have metastatic cancer, which has no treatment and detrimental outcomes in most cases.

25 Jul 2014

Neurosurgeons develop new technologies to perform highly complex brain surgery

In a milestone procedure, neurosurgeons at UC San Diego Health System have integrated advanced 3D imaging, computer simulation and next-generation surgical tools to perform a highly complex brain surgery through a small incision to remove deep-seated tumors.

25 Jul 2014

Novocure: 18 physicians certified to prescribe NovoTTF Therapy in Europe and Israel

Novocure, a commercial stage oncology company, announced today that 18 prominent neurosurgeons and neuro-oncologists at medical centers in Europe and Israel are trained and certified to prescribe NovoTTF Therapy.

15 Jul 2014

Scientists find a new strategy for brain cancer treatment

Scientists at the Montreal Neurological Institute and Hospital, McGill University and McGill University Health Centre have shown that a member of the protein family known as SUMO (small ubiquitin-like modifier) is a key to why tumour cells multiply uncontrollably, especially in the case of glioblastoma. T

9 Jul 2014

Mass spectrometry-based tool successfully used in brain cancer surgery

A tool to help brain surgeons test and more precisely remove cancerous tissue was successfully used during surgery, according to a Purdue University and Brigham and Women's Hospital study.

4 Jul 2014

New collaborative fundraising effort focuses on AYA cancer

Leaders from Case Western Reserve University and University Hospitals this evening announced a new collaborative fundraising effort focused on Adolescent and Young Adult (AYA) cancer.

2 Jul 2014

Researchers identify new biomarker that predicts effectiveness of glioblastoma treatment

Researchers at the University of California, San Diego School of Medicine have identified a new biomarker that predicts whether glioblastoma - the most common form of primary brain cancer - will respond to chemotherapy. The findings are published in the July print issue of Oncotarget.

2 Jul 2014

Prophage autologous cancer vaccine extends survival in patients with newly diagnosed GBM

Agenus Inc., announced final results from a single-arm, multi-institutional, open-label, Phase 2 study showing that patients with newly diagnosed glioblastoma multiforme (GBM) who received Agenus' Prophage autologous cancer vaccine added to the standard of care treatment, lived nearly twice as long as expected.

1 Jul 2014

MagForce publishes operative highlights and financial results for fiscal year 2013

MagForce AG, a leading medical device company in the field of nanomedicine focused on oncology, published today its financial results for the fiscal year ending on December 31, 2013 and operative highlights.

30 Jun 2014

Scientists report first successful step toward vaccine that targets mutation in brain cancer

Astrocytomas and oligodendrogliomas are subtypes of a brain cancer called 'glioma'. These incurable brain tumors arise from glial cells, a type of support cell found in the central nervous system.

26 Jun 2014

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV nanocells packaged with doxorubicin for the treatment of recurrent glioblastoma (GBM), a common and aggressive type of brain tumor.

26 Jun 2014

Researchers identify two oncogenes that drive the development of medulloblastoma

A new collaborative study carried out by researchers at Sanford-Burnham Medical Research Institute, UC San Diego, the German Cancer Research Center, the University of Heidelberg (Germany), and 33 other research institutions has identified two oncogenes, called GFI1 and GFI1B, that drive the development of medulloblastoma, the most common malignant brain tumor in children.

23 Jun 2014

Researchers shed new light on how gliomas cells migrate in brain and cause devastating tumors

Researchers at the University of Alabama at Birmingham have shed new light on how cells called gliomas migrate in the brain and cause devastating tumors.

20 Jun 2014

New class of tumor-targeting agents can seek out dozens of solid tumors

Scientists at the University of Wisconsin Carbone Cancer Center (UWCCC) report that a new class of tumor-targeting agents can seek out and find dozens of solid tumors, even illuminating brain cancer stem cells that resist current treatments.

13 Jun 2014

EU-funded project aims to identify potential new targets for cancer therapy

Targeted therapies have revolutionised the treatment of cancer since they were first introduced. Amongst the first medications approved in Europe, was the breast cancer drug Herceptin, which was approved in 2000. Then, the drug Glivec, was initially introduced to treat a certain form of leukaemia, and approved in 2001. Targeted therapies specifically inhibit molecules within so-called signalling pathways that usually control cell growth, death and differentiation. If they are altered, for example falsely inactivated or activated, the cells may start growing in an uncontrolled manner.

11 Jun 2014

Northwest Biotherapeutics initiates Phase III trial of DCVax-L in Germany

Northwest Biotherapeutics, a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, announced today that it has initiated the Phase III trial of DCVax-L in Germany.

10 Jun 2014

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.

10 Jun 2014

Gene variants that lead to longer telomeres boost brain cancer risk

New genomic research led by UC San Francisco scientists reveals that two common gene variants that lead to longer telomeres, the caps on chromosome ends thought by many scientists to confer health by protecting cells from aging, also significantly increase the risk of developing the deadly brain cancers known as gliomas.

9 Jun 2014

Synthetic peptide carrier delivers drugs through blood-brain barrier for cancer treatment

Researchers at Mayo Clinic have demonstrated in a mouse model that their recently developed synthetic peptide carrier is a potential delivery vehicle for brain cancer chemotherapy drugs and other neurological medications. The findings appear in PLOS ONE.

4 Jun 2014